Cross-talk between the ErbB/HER family and the IGFR-I receptor signaling pathway has been described and suggested as a possible mechanism of resistance in breast cancer patients treated with the anti-HER2/neu antibody trastuzumab [10], [29]. Here, ERBB2 is linked to breast cancer.